A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs GEN 003 (Primary) ; Matrix M
- Indications Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences
- 28 Jul 2017 According to a Genocea Biosciences media release, data will be presented at the 42nd Annual International Herpesvirus Workshop 2017.
- 24 Jul 2017 12-month top-line data from this trial published in a Genocea Biosciences media release.
- 09 Jun 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History